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Background: Allergic rhinitis is a symptomatic allergic disease of the nose that affects 10 to 20% of the global
population. Chinese otolaryngologists use one acupuncture needle to stimulate the sphenopalatine ganglion
because of its potential advantages for treating moderate-severe persistent allergic rhinitis compared with
traditional Chinese acupuncture (verum acupuncture); however, little evidence is available to support the wide
clinical use thus far. Therefore, we propose a protocol for a parallel, multicenter, assessor-blinded, randomized
controlled trial to evaluate sphenopalatine ganglion stimulation with one acupuncture needle compared to
verum acupuncture for treatment of moderate-severe persistent allergic rhinitis.
Methods: In the trial, 96 patients previously diagnosed with moderate-severe persistent allergic rhinitis and meeting all
inclusion criteria will be allocated to one of two equal therapeutic groups by using a computer-generated randomization
list. The interventional group will receive sphenopalatine ganglion stimulation with one acupuncture needle for 4 weeks
(once or twice weekly, total four to eight sessions); attending physicians will decide whether the second session is
required in a week by examining signs and symptoms. The control group will receive individualized verum acupuncture
for 4 weeks (twice weekly, total eight sessions). Follow-up evaluations will be performed 1 month later. The primary
outcome measure is the change in the total nasal symptom score from the baseline to week 4. The secondary
outcome measures include onset time and duration of effectiveness in every session, change in number of days
with moderate-severe persistent allergic rhinitis from the baseline to week 8, change in total immunoglobulin E
level and eosinophil count in venous blood from the baseline to week 4, change in Rhinoconjunctivitis Quality
of Life Questionnaire score from the baseline to week 4, and clinical waiting time.
Discussion: The trial should provide evidence for the benefits of sphenopalatine ganglion stimulation with one
acupuncture needle for treating moderate-severe persistent allergic rhinitis, including better change in total
nasal symptom score, faster onset time, longer duration of effectiveness, and shorter treatment time.
Trial registration: Current Controlled Trials: ISRCTN21980724 (registered on 27 March 2014).
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Allergic rhinitis is a symptomatic disorder of the nose
induced by immunoglobulin E (IgE)-mediated inflamma-
tion of the nasal membranes after allergen exposure [1]
and can be classified into intermittent and persistent
allergic rhinitis (PER). It has a reported prevalence of
approximately 10 to 20% globally and 11.1% in China
[2]. Allergic rhinitis causes major illness and disability
worldwide and reduces the quality of life and productiv-
ity regardless of ethnicity, gender, and age [3]. Some pa-
tients develop asthma, further increasing medical and
social burdens.
Conventional medical treatments for PER include
H1-antihistamines, glucocorticosteroids, leukotriene an-
tagonists, decongestants, anticholinergics, and specific
immunotherapy [4]. However, several patients experi-
ence side effects, become dissatisfied, and seek comple-
mentary and alternative treatments [5,6]. In traditional
Chinese medicine, physicians have effectively used
verum acupuncture to treat allergic rhinitis for many
years [7,8]. Interestingly, a large case study suggested
that sphenopalatine ganglion stimulation with one
acupuncture needle, a technique developed by a Chin-
ese otolaryngologist and applied in more than 130,000
Chinese patients [9], offers potential advantages with
regard to nasal symptoms, onset time, duration of ef-
fectiveness, and quality of life.
A recent pilot nonrandomized study (ten patients per
group) revealed significantly improved total nasal symptom
score (TNSS [10]) (P <0.05), total non-nasal symptom score
(TNNSS [11]) (P <0.05), and Rhinoconjunctivitis Quality of
Life Questionnaire (RQLQ [12,13]) score (P <0.001) after
sphenopalatine ganglion stimulation with one acupuncture
needle than after verum acupuncture. After each session,
the onset time of effectiveness was shorter (P <0.001) and
duration of effectiveness was longer (P <0.001). Further, pa-
tients had fewer symptomatic days one month after sphe-
nopalatine ganglion stimulation (P <0.001). On the basis of
these results, we propose a protocol for a parallel multicen-
ter assessor-blinded randomized controlled trial to evaluate
sphenopalatine ganglion stimulation with one acupuncture




The study design and methodology adhere to the principles
of the Declaration of Helsinki and have been approved by
the Xiyuan Hospital Ethics Committee (December 31,
2013; approval number 2013XL062-2). The trial is regis-
tered in the ISRCTN register (Current Controlled Trials) as
ISRCTN21980724. Each participant will receive an explan-
ation regarding the study protocol and written consent will
be obtained. All participants will receive documentationregarding the study protocol and are free to withdraw at
any time.
Study setting
The study will be simultaneously conducted at Xiyuan
Hospital, Beijing Tongren Hospital, Beijing Baiwan
Chinese Medical Clinic, and Beijing Dacheng Acupuncture
Hospital, Beijing, China. It will run from January 2014 to
October 2015.
Sample size
We used the symptomatic outcome of the pilot study
(10:10 cases in each group) to calculate the sample size
in PASS 2008 software (NCSS, Kaysville, UT). The
means for the score of TNSS, serially assessed during
the 4-week treatment period, was 4.2071 ± 2.58702 after
sphenopalatine ganglion stimulation and 7.4393 ± 2.0368
after verum acupuncture. For a power of 0.9 to detect a
significant difference (α = 0.01, two sided), 15 partici-
pants per group are required. Forty cases will be enrolled
in consideration of four centers’ research capabilities.
Allowing for a 20% dropout rate, 48 participants will be
enrolled in each group, yielding 96 patients for the
study.
Recruitment
Patients will be recruited from the outpatient clinics of
the four participating hospitals. Posters describing the
required population, free blood and allergic testing of
eligible patients, and contact information of the re-
searcher will also be displayed in the clinics. Moreover,
television advertisements will be used to publicize the
recruitment.
Baseline assessment
During the run-in period (baseline), the physical sign
score (measured at least twice), TNSS and TNNSS (mea-
sured once daily), RQLQ score (measured at least once),
and total IgE level and eosinophil count in venous blood
will be determined.
Inclusion criteria
To be eligible, participants should be previously diagnosed
with moderate-severe PER, according to the Allergic
Rhinitis and Its Impact on Asthma (ARIA) criteria,
and meet the following requirements:
1. Have had PER for more than 4 days/week, and more
than 4 consecutive weeks, with a disease course of
more than 1 year.
2. Age range from 18 to 60 years.
3. Completed AR baseline questionnaire and provided
written informed consent.
4. Physical sign score ≥1 and symptom score ≥4.
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Patients will be excluded if they meet the following
criteria:
1. Acute sinusitis, active asthma, or diagnosis or
suspicion of pneumonia.
2. Nasal abnormalities or rhinopolypus (polypoid
lesions can be included).
3. Consumed antihistamines, anticholinergics,
corticosteroids, decongestants or antibiotics within
2 weeks before enrollment.
4. Received systemically administered corticosteroids
within 6 months or special immune therapy within
1 year before enrollment.
5. Received an alternative and complementary
modality, that is, acupuncture or herbal medication,
for treatment of AR within 2 months before
enrollment.
6. Pregnancy or planning for pregnancy.
7. Serious medical conditions such as uncontrolled
hypertension, diabetes mellitus requiring insulin
injection, past or current malignant tumor, severe
dyslipidemia or liver and kidney dysfunction,
anemia, active pulmonary tuberculosis, other
infectious diseases, or systemic diseases that
cannot be treated by acupuncture.
8. Heavy smoker.
Randomization and blinding
This is a multicenter prospective, randomized con-
trolled clinical trial. The central randomization will be
executed by the Xiyuan Hospital, which will use block
randomization to generate the random allocation se-
quence and prepare predetermined computer-made
randomization opaque sealed envelopes. The enve-
lopes will be numbered consecutively and connected
into a strain. Each envelope will be separated from the
strain and then opened in sequence only after the run-
in period when the participants are registered in the
trial. Outcome assessors and personnel who deal with
the data collection and data analysis will be blinded
throughout the entire trial. The acupuncturist and pa-
tients cannot be blinded because of the nature of the
two different acupuncture techniques in this trial, but
the physicians are trained not to communicate with
the participants or outcome assessors regarding the
treatment procedures and responses. To ensure that
all practices at each of the four hospitals are the same,
physicians who will enroll participants and assessors
who will collect data in the four hospitals will be asked
to have a 3-day training seminar concerning treatment
modalities and trial documentation prior to the trial.
Periodic check-ups on the practices will be performed
in each hospital.Procedure
Based on the predetermined randomization envelopes,
participants will be randomly allocated to the interven-
tion group or control group (Figure 1). The patients will
have an equal probability of being assigned to either of
the two groups. Participants will be asked to record
symptoms in a rhinitis diary from the run-in period to
the 4th week after randomization, and the usage of acute
symptomatic relief medication will be recorded during
the treatment period. The case report form contains all
of the outcome measures and the rhinitis diary will
be collected separately from the four hospitals in the
4th week after randomization by blinded interviewers.
Blinded telephone interviewers will contact the partici-
pants regarding the days of moderate to severe allergic
rhinitis during the 4 weeks after the treatment period to
evaluate the long-term effect of acupuncture in the 8th
week after randomization.
Interventions
Participants will undergo a standardized interview and
receive further information regarding the study. Acu-
puncturists for the control group must have over
10 years of clinical experience and an acupuncture li-
cense issued by the Ministry of Health of the People’s
Republic of China. In addition to these criteria, acu-
puncturists for the interventional group must have
been trained by Professor Li Xinwu, the inventor of
the sphenopalatine ganglion stimulation technique;
have relevant neuroanatomic knowledge; be able to
perform the technique clinically; have practiced no
fewer than 10 times under Professor Li Xinwu’s super-
vision; and have practiced independently no fewer
than 2,000 times. Before the trial, all acupuncturists
will receive special training in the purpose and proce-
dures of the trial, therapeutic strategies, and quality
control.
Patients will receive 4 weeks of treatment. In the inter-
ventional group, the acupuncturists will use one dispos-
able sterile acupuncture needle (0.35 mm diameter,
60 mm length; Beijing Zhongyan Taihe Medicine Co.,
Beijing, China) to stimulate the sphenopalatine ganglion.
After local disinfection, the needle will be gradually
inserted between the zygomatic arch and the coronoid
process of the mandible to a depth of approximately
55 mm to enter the pterygopalatine fossa. An additional
picture file shows this in more detail [see Additional file
1]. Once the needle touches the sphenopalatine ganglion
and the patient experiences a special sensation (radiating
toward the nose), the patient will signal with the hand
and the needle will be withdrawn immediately. The
sphenopalatine ganglion will be stimulated unilaterally
in a session. Patients will receive 1 or 2 sessions a week,
but most will need only 1 weekly session. The physician
Figure 1 CONSORT flow diagram.
Table 1 Verum acupuncture points and techniques for






Transversely along the nasolabial sulcus
and toward the root of the nose
10 to 15
Yintang (GV29) Transversely and downward toward
the nose
10 to 15
Fengchi (GB20) Obliquely toward the tip of the nose 13 to 20
Fengfu (GB16) Perpendicular to the skin 13 to 20
Zusanli (ST36) Perpendicular to the skin between
the tibia and the fibula
20 to 30
Adjunct
Shangxing (GV23) Transversely toward the calvarium 8 to 13
Hegu (LI4) Perpendicular to the skin 13 to 25
Kouheliao (LI19) Obliquely toward the tip of the nose 5 to 8
Feishu (BL13) Obliquely toward the spine 13 to 20
Pishu (BL20) Obliquely toward the spine 13 to 20
Shenshu (BL23) Perpendicular to the skin 15 to 25
Sanyinjiao (SP36) Perpendicular to the skin 13 to 25
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basis of physical signs and symptoms during the second
visit of the week.
The control group will undergo 2 sessions of verum acu-
puncture per week. The acupoints, including the main and
adjunct points (Table 1), have been selected on the basis of
Chinese medicine guidelines for allergic rhinitis [14] and
are described according to standard nomenclature [15].
Two main and two adjunct points will be applied accord-
ing to each patient’s symptoms. In particular, 32-gauge
(0.25 mm diameter, 25 mm length) sterile needles (Beijing
Zhongyan Taihe Medicine Co.) will be used for facial,
head, and back points, whereas 30-gauge (0.3 mm diam-
eter, 40 mm length) sterile needles (Beijing Zhongyan
Taihe Medicine Co.) will be used for limb and lumbar
points. The depth of insertion will vary between 10 and
30 mm (details in Table 1). The acupuncturists will manu-
ally manipulate the acupuncture needles until de-qi (that
is, sensation of tenseness around the needle felt by the
practitioner and numbness, distension, soreness, and
heaviness around the acupoint felt by the patient) and
maintain the needle position for 25 minutes.
Outcome measures
The primary outcome measure is the change in TNSS
between the baseline (week 0) and week 4. The second-
ary outcome measure include the change in TNNSS
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and duration of effectiveness in every session, change in
the number of symptomatic days from the baseline to
the end of the follow-up (week 8), change in total IgE
level and eosinophil count in venous blood from the
baseline to week 4, change in RQLQ score from the
baseline to week 4, and clinical waiting time (Table 2).
Onset time is the timing of changes in the physical
sign score and nasal congestion degree. The physical
sign score will be calculated from the degree of inferior
nasal concha swelling [16] before and after each session.
The nasal congestion degree will be scored using a visual
analog scale [17] before and after each session. The
duration of effectiveness will be recorded as the duration
of change in TNSS after each session (once the patient
feels symptom alleviation).
Data collection
During the study, data will be collected before and after
each session and in weeks 0, 4 and 8. The physical sign
score will be calculated by outcome assessors approxi-
mately 10 to 18 times (week 0, before and after each
session), and the RQLQ score will be subjectively deter-
mined at least five times (once a week). The total IgE
level and eosinophil count in venous blood will be mea-
sured in weeks 0 and 4.
Participants will be asked to record symptoms from the
baseline to week 4 in a rhinitis diary. They will be required
to note the use of relief medication (cetirizine dihy-
drochloride film-coated tablets) prescribed by the physi-
cians for acute symptoms of allergic rhinitis, including
dosage, ingestion time, relief time, and side effects. TheTable 2 Outcome measurements
Week 0
Baseline











Duration of effectiveness in every session
Waiting time
Adverse event
TNSS, Total nasal symptom score; TNNSS, Total non-nasal symptom score; RQLQ, Rhcase report form containing data for outcome measures
and the rhinitis diary will be collected separately from the
hospitals by blinded interviewers in week 4. Blinded tele-
phonic interviewers will contact participants regarding the
number of moderate-severe symptomatic days with PER
up to week 8. Participants will also be asked to report any
adverse events including discomfort, bruising, or subcuta-
neous hematoma around the insertion site; nausea; or feel-
ing faint after each treatment.
Compliance and reasons for discontinuation will be
documented in the case report form until week 8. In
dropout cases, participants will be contacted by tele-
phone or mail to ascertain the reasons and record the
time of the last treatment and last assessment. For with-
drawal caused by adverse events or dissatisfaction with
the treatment, participants will receive other suitable
treatments.
Statistical analysis
Data will be analyzed by the following principles: (i)
intention-to-treat analysis (participants who have at least
one measurable outcome after treatment; missing data
will be replaced according to the principle of last obser-
vation carried forward) and (ii) and per-protocol analysis
(participants who have completed the study). A variance
analysis will be performed to reject the global hypothesis
that “There is no difference in all fields of means be-
tween the groups.” The significance level is 5%; therefore
P <0.05 indicates a significance difference.
The means of TNSS and TNNSS will be compared by
analysis of variance (ANOVA) for repeated measures
between the groups. Mean onset time and duration of1 2 3 4 5 6 7 8
Treatment period (4 to 8 session) Follow-up
√ √ √ √
√ √ √ √
√ √ √ √




√ √ √ √
√ √ √ √
√ √ √ √
√ √ √ √
inoconjunctivitis Quality of Life Questionnaire.
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groups. Analysis of variance (ANOVA) for repeated
measures will be used for between-group comparisons
of RQLQ scores. The other continuous variables (total
IgE level and eosinophil count in venous blood, number
of symptomatic days, and clinical waiting time) will be
compared by t-test. Comparisons within groups will be
performed by multivariate ANOVA followed by Tukey’s
post hoc test. Stratified analysis within the four hospitals
will be performed to control for confounding factors, if
necessary. The incidence of adverse events will be calcu-
lated and compared between the groups by using the
chi-squared test or Fisher’s exact test. All analyses will
be performed in SPSS version 13.0 (SPSS, Chicago, IL).
Discussion
Sphenopalatine ganglion stimulation with one acupunc-
ture needle requires knowledge of not only traditional
Chinese medicine theory but also neuroanatomy and
neurophysiology. Furthermore, it is relatively difficult to
study and apply clinically. Considering the proven thera-
peutic efficiency of verum acupuncture for PER, clinical
application of a new technique will be unwarranted if
evidence for its advantages cannot be obtained.
The proposed randomized controlled trial will investigate
the advantages of sphenopalatine ganglion stimula-
tion with one acupuncture needle over verum acu-
puncture for treating moderate-severe PER. The trial
should show benefits of sphenopalatine ganglion stimu-
lation with an acupuncture needle for treatment of
moderate-severe persistent allergic rhinitis, including
improvement of the total nasal symptom score, faster
onset time, longer duration of effectiveness and shorter
treatment time.
Many Chinese acupuncturists and otolaryngologists
have discussed the endpoints for our pilot study and
concluded that inferior nasal concha swelling and nasal
congestion are the most serious challenges in traditional
Chinese acupuncture. Further, such treatment does not
show clinical effectiveness in a short time. In contrast,
sphenopalatine ganglion stimulation with one acupunc-
ture needle can quickly alleviate nasal congestion and in-
ferior nasal concha swelling. Therefore, we have decided
to observe the onset time and duration of effectiveness
in addition to other outcome measures such as TNSS
and TNNSS used in other studies.
Our pilot study revealed that sphenopalatine ganglion
stimulation with one acupuncture needle yields signifi-
cant differences in onset time, duration of effectiveness,
TNSS, RQLQ score, and number of post-treatment symp-
tomatic days compared with verum acupuncture. Experts
in allergic rhinitis were consulted to decide which end-
points to adopt for sample size calculation. They concluded
that changes in TNSS are generally applied, and thisscoring system has been validated [18]. Therefore, the mean
TNSS was used to calculate the sample size for the trial.
Furthermore, the research group consensually decided
that TNSS should replace onset time and duration of
effectiveness, reported in the ISRCTN registry, as the
primary outcome measure of the trial. Only 15 cases
per group, total 30, are needed based on the sample
calculation. As the small sample size may be increase
the risk of bias, we decided to increase the patient
number to 40 in each group in consideration of each
center’s research capabilities. Allowing a drop-out rate
of 20%, 96 participants will be enrolled in the study.
All other endpoints are considered as secondary out-
come measures. The total IgE level and eosinophil
count in venous blood will be measured to investigate
the mechanism underlying the effect of acupuncture.
We will measure the clinical waiting time to investigate
economic benefits. Sphenopalatine ganglion stimulation
with an acupuncture needle requires only approximately
1.5 min and no bed. In contrast, patients spend an average
of 2 h to receive acupuncture in Chinese hospitals, includ-
ing 1.5 h or longer waiting for a bed and 20 min or longer
per session.
The proposed trial has several methodological limita-
tions. The acupuncturists and participants cannot be
blinded because of the difference in acupuncture tech-
niques and control required while needling. However,
the acupuncturists will be trained to not communicate
the therapeutic procedures and responses to the partici-
pants and outcome assessors. Furthermore, this study
will not allow us to determine whether the observed effi-
cacy is caused by placebo effects, intensity of provider
contact, or physiological effects of needling. The bias
resulting from the lack of blinding cannot be totally ex-
cluded. Finally, the sample size is small.Trial status
The trial is currently in the recruitment phase.Additional file
Additional file 1: The insertion point and the Pterygopalatine fossa.
The additional file will present two figures giving more details. (a) insertion
point for sphenopalatine ganglion stimulation (the figure is cited from the
article: Grégoire et al. [19]). (b) The red arrow points out the Pterygopalatine
fossa in the skull.Abbreviations
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Nonnasal Symptom Score.
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